Search hospitals > Virginia > Norfolk
Virginia Oncology Associates
Claim this profileNorfolk, Virginia 23502
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
228 reported clinical trials
9 medical researchers
Summary
Virginia Oncology Associates is a medical facility located in Norfolk, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Virginia Oncology Associates is involved with conducting 228 clinical trials across 127 conditions. There are 9 research doctors associated with this hospital, such as Michael A. Danso, Michael McCollum, Paul Conkling, MD, and Mark Fleming, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Lung Cancer
Global LeaderStage III
Stage I
Stage II
Top PIs
Michael A. DansoVirginia Oncology Associates1 year of reported clinical research
Expert in Breast Cancer
Studies Tumors
14 reported clinical trials
24 drugs studied
Michael McCollumVirginia Oncology Associates2 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
8 reported clinical trials
15 drugs studied
Paul Conkling, MDVirginia Oncology Associates4 years of reported clinical research
Studies Cancer
Studies Adenocarcinoma
4 reported clinical trials
10 drugs studied
Mark Fleming, MDVirginia Oncology Associates .3 years of reported clinical research
Studies Prostate Cancer
4 reported clinical trials
7 drugs studied
Clinical Trials running at Virginia Oncology Associates
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Pancreatic Cancer
Follicular Lymphoma
Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma
ALK Gene Rearrangement
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Giredestrant + Phesgo
for Breast Cancer
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.
Recruiting2 awards Phase 311 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Virginia Oncology Associates?
Virginia Oncology Associates is a medical facility located in Norfolk, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Virginia Oncology Associates is involved with conducting 228 clinical trials across 127 conditions. There are 9 research doctors associated with this hospital, such as Michael A. Danso, Michael McCollum, Paul Conkling, MD, and Mark Fleming, MD.